FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303520909> ?p ?o ?g. }

• W4303520909 endingPage "839.e5" @default.
• W4303520909 startingPage "828" @default.
• W4303520909 abstract "Multimodality treatment for resectable non-small cell lung cancer has long remained at a therapeutic plateau. Immune checkpoint inhibitors are highly effective in advanced non-small cell lung cancer and promising preoperatively in small clinical trials for resectable non-small cell lung cancer. This large multicenter trial tested the safety and efficacy of neoadjuvant atezolizumab and surgery.Patients with stage IB to select IIIB resectable non-small cell lung cancer and Eastern Cooperative Oncology Group performance status 0/1 were eligible. Patients received atezolizumab 1200 mg intravenously every 3 weeks for 2 cycles or less followed by resection. The primary end point was major pathological response in patients without EGFR/ALK+ alterations. Pre- and post-treatment computed tomography, positron emission tomography, pulmonary function tests, and biospecimens were obtained. Adverse events were recorded by Common Terminology Criteria for Adverse Events v.4.0.From April 2017 to February 2020, 181 patients were entered in the study. Baseline characteristics were mean age, 65.1 years; female, 93 of 181 (51%); nonsquamous histology, 112 of 181 (62%); and clinical stages IIB to IIIB, 147 of 181 (81%). In patients without EGFR/ALK alterations who underwent surgery, the major pathological response rate was 20% (29/143; 95% confidence interval, 14-28) and the pathological complete response rate was 6% (8/143; 95% confidence interval, 2-11). There were no grade 4/5 treatment-related adverse events preoperatively. Of 159 patients (87.8%) undergoing surgery, 145 (91%) had pathologic complete resection. There were 5 (3%) intraoperative complications, no intraoperative deaths, and 2 postoperative deaths within 90 days, 1 treatment related. Median disease-free and overall survival have not been reached.Neoadjuvant atezolizumab in resectable stage IB to IIIB non-small cell lung cancer was well tolerated, yielded a 20% major pathological response rate, and allowed safe, complete surgical resection. These results strongly support the further development of immune checkpoint inhibitors as preoperative therapy in locally advanced non-small cell lung cancer." @default.
• W4303520909 created "2022-10-08" @default.
• W4303520909 creator A5000609254 @default.
• W4303520909 creator A5002656601 @default.
• W4303520909 creator A5003251023 @default.
• W4303520909 creator A5004054300 @default.
• W4303520909 creator A5009359434 @default.
• W4303520909 creator A5009470333 @default.
• W4303520909 creator A5010278316 @default.
• W4303520909 creator A5019416691 @default.
• W4303520909 creator A5021339490 @default.
• W4303520909 creator A5033156221 @default.
• W4303520909 creator A5034467403 @default.
• W4303520909 creator A5034705456 @default.
• W4303520909 creator A5039791495 @default.
• W4303520909 creator A5042586171 @default.
• W4303520909 creator A5043558092 @default.
• W4303520909 creator A5048361872 @default.
• W4303520909 creator A5050905254 @default.
• W4303520909 creator A5051283101 @default.
• W4303520909 creator A5053521833 @default.
• W4303520909 creator A5055597008 @default.
• W4303520909 creator A5059652753 @default.
• W4303520909 creator A5060083195 @default.
• W4303520909 creator A5060287300 @default.
• W4303520909 creator A5064494204 @default.
• W4303520909 creator A5071670695 @default.
• W4303520909 creator A5082266835 @default.
• W4303520909 creator A5090385143 @default.
• W4303520909 creator A5091280788 @default.
• W4303520909 creator A5091299701 @default.
• W4303520909 date "2023-03-01" @default.
• W4303520909 modified "2023-10-18" @default.
• W4303520909 title "Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer" @default.
• W4303520909 cites W1817196311 @default.
• W4303520909 cites W1954745527 @default.
• W4303520909 cites W1972362650 @default.
• W4303520909 cites W2066968134 @default.
• W4303520909 cites W2072100134 @default.
• W4303520909 cites W2104325484 @default.
• W4303520909 cites W2104504726 @default.
• W4303520909 cites W2114238186 @default.
• W4303520909 cites W2120844381 @default.
• W4303520909 cites W2125736059 @default.
• W4303520909 cites W2128147114 @default.
• W4303520909 cites W2134291074 @default.
• W4303520909 cites W2143861118 @default.
• W4303520909 cites W2160708645 @default.
• W4303520909 cites W2182482244 @default.
• W4303520909 cites W2228221433 @default.
• W4303520909 cites W2263759961 @default.
• W4303520909 cites W2293531514 @default.
• W4303520909 cites W2521503673 @default.
• W4303520909 cites W2527905628 @default.
• W4303520909 cites W2538232731 @default.
• W4303520909 cites W2749232358 @default.
• W4303520909 cites W2762777471 @default.
• W4303520909 cites W2796582438 @default.
• W4303520909 cites W2798160602 @default.
• W4303520909 cites W2803847828 @default.
• W4303520909 cites W2805354595 @default.
• W4303520909 cites W2892640821 @default.
• W4303520909 cites W2893824814 @default.
• W4303520909 cites W2905289065 @default.
• W4303520909 cites W2913928546 @default.
• W4303520909 cites W2925446385 @default.
• W4303520909 cites W3005124847 @default.
• W4303520909 cites W3132841322 @default.
• W4303520909 cites W3190268632 @default.
• W4303520909 cites W4206710770 @default.
• W4303520909 cites W4226382697 @default.
• W4303520909 cites W4295442856 @default.
• W4303520909 cites W93292047 @default.
• W4303520909 cites W1964968836 @default.
• W4303520909 doi "https://doi.org/10.1016/j.jtcvs.2022.10.007" @default.
• W4303520909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36369159" @default.
• W4303520909 hasPublicationYear "2023" @default.
• W4303520909 type Work @default.
• W4303520909 citedByCount "6" @default.
• W4303520909 countsByYear W43035209092023 @default.
• W4303520909 crossrefType "journal-article" @default.
• W4303520909 hasAuthorship W4303520909A5000609254 @default.
• W4303520909 hasAuthorship W4303520909A5002656601 @default.
• W4303520909 hasAuthorship W4303520909A5003251023 @default.
• W4303520909 hasAuthorship W4303520909A5004054300 @default.
• W4303520909 hasAuthorship W4303520909A5009359434 @default.
• W4303520909 hasAuthorship W4303520909A5009470333 @default.
• W4303520909 hasAuthorship W4303520909A5010278316 @default.
• W4303520909 hasAuthorship W4303520909A5019416691 @default.
• W4303520909 hasAuthorship W4303520909A5021339490 @default.
• W4303520909 hasAuthorship W4303520909A5033156221 @default.
• W4303520909 hasAuthorship W4303520909A5034467403 @default.
• W4303520909 hasAuthorship W4303520909A5034705456 @default.
• W4303520909 hasAuthorship W4303520909A5039791495 @default.
• W4303520909 hasAuthorship W4303520909A5042586171 @default.
• W4303520909 hasAuthorship W4303520909A5043558092 @default.
• W4303520909 hasAuthorship W4303520909A5048361872 @default.
• W4303520909 hasAuthorship W4303520909A5050905254 @default.

• next